title: Synthetic lethality: emerging targets and opportunities in melanoma.
abstract: Great progress has been made in the treatment of melanoma through use of targeted therapies and immunotherapy. One approach that has not been fully explored is synthetic lethality, which exploits somatically acquired changes, usually driver mutations, to specifically kill tumour cells. We outline the various approaches that may be applied to identify synthetic lethal interactions and define how these interactions may drive drug discovery efforts.
authors.affiliation: Experimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, UK.
authors.forename: Nicola
authors.initials: N
authors.lastname: Thompson
authors.affiliation: Experimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, UK.
authors.forename: David J
authors.identifier: 0000-0001-9490-0306
authors.initials: DJ
authors.lastname: Adams
authors.affiliation: Experimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, UK.
authors.forename: Marco
authors.initials: M
authors.lastname: Ranzani
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D055808:Drug Discovery; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics*; D058990:Molecular Targeted Therapy; D000072020:Synthetic Lethal Mutations / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents
keywords: CRISPR; melanoma genomics; preclinical models; synthetic lethality; therapeutic target